Akeso Inc. has announced the enrollment of the first patient in a Phase III clinical trial of ivonescimab for the treatment of metastatic pancreatic cancer. This trial, designated AK112-310/HARMONi-GI2, will investigate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with chemotherapy, with or without ligufalimab, a CD47 monoclonal antibody. The study aims to address the current lack of effective first-line immunotherapy options for metastatic pancreatic cancer, a condition known for its resistance to existing treatments. Co-principal investigators include Professor Yu Xianjun from Fudan University Shanghai Cancer Center, Professor Ying Jie'er from Zhejiang Cancer Hospital, and Professor Tai Sheng from Harbin Medical University Cancer Hospital. The results of this pivotal trial are expected to be presented in the future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。